Contact Information
Company Information
Company
Tizona Therapeutics, Inc.
Total Funding
370000000.0
Technologies
Outlook
Amazon AWS
Mobile Friendly
Apache
Google Tag Manager
Remote
AI
Keywords
immuneoncology therapeutics
biotechnology research
cancer immunotherapy
first-in-class
hla-g antagonist
ttx-080
clinical trials
immune evasion
biomarker-defined
metastatic colorectal cancer
egfr inhibitor
cetuximab
immune checkpoint
tumor immunology
antibody therapy
tumor microenvironment
immuno-oncology
progression-free survival
overall response rate
treatment outcomes
drug development
clinical data
phase 1b
oncology research
immune suppression
therapy resistance
scientific breakthroughs
patient enrollment
anti-tumor activity
clinical efficacy
pharmacodynamic biomarkers
phase 1 clinical trial
cancer treatment
translational medicine
treatment options
immune activation
natural killer cells
cytokines
tumor-infiltrating lymphocytes
cancer progression
tumor antigens
therapeutic candidates
therapeutic development
cancer therapeutics
regulatory pathways
cancer research
scientific advisors
biopharmaceuticals
immunotherapeutic agents
strategic alliances
drug design
patient outcomes
health care
health
wellness & fitness
hospital & health care
Get Full Contact Details
Subscribe to reveal email addresses and export contacts.
View Plans